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Abstract
Background: Insulin resistance is associated with obesity, glucose intolerance or diabetes, 
hypertension, dyslipidemia, and cardiovascular disease. Constellation of these risk factors is 
called metabolic syndrome (MetS). MetS is common among postmenopausal women. Low sex 
hormone binding globulin (SHBG) levels associate with an increased risk of MetS in postme-
nopausal women. Variations in SHBG gene associate with low levels of circulating SHBG le-
vels. We aim to study the association between SHBG gene polymorphisms — rs1799941 (A/G) 
and rs6257 (T/C) — with MetS among postmenopausal women. 
Methods: The study population consisted of 182 postmenopausal women with MetS and 
119 control subjects. We analyzed the allele frequencies of SHBG gene polymorphisms in rela-
tion to the risk components of MetS. 
Results: MetS patients displayed significantly lower SHBG levels compared to the lean control 
subjects (p = 0.036). rs1799941 A allele was associated with high SHBG levels (p = 0.031), 
low blood pressure, body mass index and waist circumference. The number of ‘high risk’ alleles 
(G allele of the rs1799941 and T allele of rs6257) correlated positively with waist circumference 
(r = 0.203, p = 0.006) and negatively with SHBG levels (r = –0.291, p = 0.024).
Conclusions: SHBG gene polymorphisms associate with SHBG levels and MetS risk com-
ponents among postmenopausal women. Hence, A allele (rs1799941) may have a protective 
effect for MetS through its association with high SHBG levels among postmenopausal women. 
(Cardiol J 2013; 20, 3: 287–293)
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Introduction
Current smoking, dyslipidemia, elevated blood 
pressure, overweight and obesity remain as major 
causes of morbidity and mortality from cardiova-
scular disease, thrombosis, stroke, kidney disease, 
and diabetes mellitus throughout the world [1, 2]. 
Insulin resistance is associated with obesity, glu-
cose intolerance or diabetes, hypertension, dysli-
pidemia, and cardiovascular disease. Constellation 
of these risk factors is called metabolic syndrome 
(MetS) [1–3]. Sex hormones are important in the 
modulation of insulin resistance and MetS [4]. 
Decline in sex hormone levels may contribute to 
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the increasing cardiovascular risk and MetS occur-
ring in postmenopausal women. Low levels of sex 
hormone binding globulin (SHBG) indicate a higher 
risk of MetS and components in postmenopausal 
women [4–6]. Similar observations were made in 
men [7] and postmenopausal women [8]. Thus, it 
is likely that the relationship of sex hormones and 
MetS is through low SHBG levels. For instance, in 
a cohort of elderly Turkish men and women; type 
2 diabetes mellitus, elevated apolipoprotein B and 
triglyceride, or reduced high density lipoprotein 
cholesterol (HDL-C) levels were all associated 
with low SHBG levels [4, 5]. Hence, low SHBG 
level is a valuable biomarker of increased cardio-
metabolic risk in postmenopausal women. 
Genetic variations in the SHBG gene affect 
the circulating sex hormone levels [9–11]. There-
fore, genetic factors that lower SHBG levels may 
potentially result in type 2 diabetes mellitus, high 
blood pressure, and obesity [9]. In fact, previous 
studies show that SHBG gene polymorphisms as-
sociate with insulin resistance [6]. G allele of the 
rs1799941 and T allele of rs6257 polymorphisms 
of SHBG gene result in low SHBG levels [10, 11]. 
Metabolic syndrome is extremely common 
(40%) among Turkish postmenopausal women 
[12]. We aim to examine the association between 
the SHBG gene polymorphisms (rs1799941 A/G 
and rs6257 T/C) and MetS risk components among 
postmenopausal Turkish women.
Methods
Study population
The study population consists of postmeno-
pausal women (age > 50). Patients were selected 
from consecutive subjects who applied to outpa-
tient clinics between June 2009 and June 2010. 
MetS is defined according to the National Choles-
terol Education Program (NCEP), Adult Treatment 
Panel III criteria [13]. The NCEP definition is based 
on the presence of 3 or more of the 5 risk criteria: waist 
circumference (> 88 cm), elevated triglycerides 
(> 150 mg/dL), reduced HDL-C (< 50 mg/dL), 
elevated blood pressure (> 130/85 mm Hg or his-
tory of hypertension) and elevated fasting glucose 
(> 110 mg/dL or history of adult onset diabetes 
mellitus).
Postmenopausal state was confirmed by histo-
ry and clinical evaluation. We selected women older 
than 50 years who had not menstruated for at least 
1 year and/or had not taken hormone replacement 
therapy for at least 3 months prior to the sampling. 
Subjects with concomitant malignancy, end stage 
renal disease, vasculitis and other chronic medical 
conditions were excluded from the study (nearly 
20%). Lean postmenopausal women (body mass 
index [BMI] < 25 kg/m2) without history of dia-
betes mellitus, hypertension and hyperlipidemia 
were selected as the control group. 
The study was approved by the local Ethics 
Committee of the Marmara University Medical 
School. Written consent was obtained from all the 
subjects.
Measurements 
Blood pressure and anthropometric measu-
rements were collected by standardized methods. 
The weight of subjects wearing minimal clothing 
was measured to the nearest 0.1 kg with a portable 
electronic scale. Each time it was moved, the scale 
was recalibrated and standardized. Height was 
measured with fiberglass tape. BMI was calculated 
as weight [kg]/height2 [m2]. Body circumferences 
were measured with subjects in the standing po-
sition. Waist (just above the iliac crest) circumfe-
rence was measured to the nearest 0.1 cm. Blood 
pressure was measured 3 times by an automatic 
blood pressure monitor (Omron®) while the subje-
cts were seated, and the last 2 measurements were 
averaged for analysis. Medium and large-sized cuff 
were used for arm circumferences of 22–32 and 
> 32 cm, respectively. 
Laboratory procedures
Fasting blood samples were collected at 9.00 a.m. 
and serum levels of fasting blood glucose, HDL-C, 
triglyceride and SHBG were measured at the Uni-
versity laboratories. Two milliliters of venous blood 
were collected from the study subjects into the 
tubes containing ethylenediamine tetraacetic acid, 
then stored at +4°C. Genomic DNA was isolated 
from peripheral blood leukocytes using a High Pure 
PCR Template Preparation Kit (Roche Diagnostics, 
Mannheim, Germany) within 1 week. Genotyping 
of the rs6257 and rs1799941 polymorphisms was 
performed by real time PCR using fluorescence 
melting curve detection analysis by means of 
the Light Cycler 1.5 System (Roche Diagnostics, 
Mannheim, Germany). Primers and hybridization 
probes were designed using GenBank reference 
sequence NG_011981. 
Hybridization probes are indicated be-
low: for rs6257 gene polymorphism, sensor 
hybridization probe was 5’-CAGCTTTGTTT- 
-GCTTTCTCTTTCTGA-fluorescein-3’and an-
chor hybridization probe was 5’-LCRed640-
-AGAGTGCCCACGACCCTCCGG-phosphate-3’. 
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For rs1799941 gene polymorphism, sensor hybrid-
ization probe was 5’-CCCACACACAAGGCTGCC- 
-fluorescein-3’ and anchor hybridization probe was 
5’-LC640-GCCTCTACACATTCTCCCAAGAGTT- 
-GTCTGA-phosphate-3’. 
The PCR run comprised 45 cycles of dena-
turation (95°C, 5 s), annealing (57°C, 20 s) and 
extension (72°C, 20 s) which followed an incuba-
tion period of 10 min to activate the FastStart Taq 
DNA Polymerase of the reaction mix (Light Cyc-
ler FastStart DNA Master Hybridization Probes, 
Roche Diagnostics, Mannheim, Germany). After 
amplification, a melting curve was generated by 
holding the reaction time at 40°C for 30 s and then 
heating slowly to 85°C with a ramp rate of 0.1°C/s.
Statistical analysis 
Power was calculated with a computer based 
program for genetic epidemiology studies (http:// 
//hydra.usc.edu/gxe), for a previously reported 28% 
difference in SHBG levels among the genotype 
groups [10], 80% power and alpha 1 error of 0.05; 
sample size was calculated as 180. Descriptive 
parameters were displayed as means ± standard 
deviation for variables with normal distribution 
and in percentages (%) for categorical variables. 
Median and interquartile range (IQR) levels were 
displayed for variables with skewed distribution. 
Student’s t test was used to analyze the differences 
in means for variables with normal distribution. 
Nonparametric test (Mann-Whitney) was used 
to compare the groups for variables with ske-
wed distribution (i.e. BMI, waist circumference, 
systolic and diastolic blood pressure, glucose, 
triglyceride, SHBG levels). c2 test was used to 
compare categorical variables between the groups. 
Nonparametric Spearman test was used to assess 
the correlation between the number of alleles — 
G (rs1799941) and T (rs6257), SHBG levels and 
the waist circumference. A p value of less than 0.05 
was accepted as statistically significant. Statistical 
analysis was performed using SPSS for Windows 
16.0 (Statistical Package for the Social Sciences 
Inc. Chicago, USA).
Results
Study population consisted of postmenopausal 
women with MetS (n = 182). Lean postmenopau-
sal women (n = 119) without history of diabetes 
mellitus, hypertension and hyperlipidemia were 
selected as the control group (mean age 60 ± 10 
vs. 61 ± 11, p = 0.606). Baseline characteristics of 
the study population are displayed in Table 1. MetS 
subjects had significantly lower SHBG and HDL-C 
levels and higher BMI, waist circumference, blood 
pressure, glucose and triglyceride levels compared 
to the control group (Table 1). 
SHBG gene polymorphisms 
The minor allelic frequencies for rs6257 (C) 
and rs1799941 (A) gene polymorphisms were 
19.1% and 16.6%, respectively. The genotype 
distributions were in accordance with the Hardy- 
-Weinberg equilibrium (p = 0.8 for rs6257 and 
p = 0.6 for rs1799941). Genotype distributions 
were similar between the study and the control 
groups (p = 0.424 [rs 1799941] and p = 0.742 
Table 1. Anthropometric and laboratory characteristics of the subjects with metabolic syndrome com-
pared with the control group.
Metabolic syndrome  
(n = 182)
Control group  
(n = 119)
P
Age [years] 60.4 ± 9.8 61.0 ± 11.0 0.606
Height [cm] 158 (5%) 160 (6%) < 0.001
Weight [kg] 82.91 ± 13.4 61.95 ± 6.7 < 0.001
Body mass index [kg/m2] 32 (6.8%) 24.15 (2.2%) < 0.001
Waist circumference [cm] 98 (12%) 84.5 (3%) < 0.001
Systolic blood pressure [mm Hg] 140 (20%) 123.5 (20%) < 0.001
Dystolic blood pressure [mm Hg] 80.5 (10%) 70 (15%) < 0.001
Glucose [mg/dL] 111 (26%) 99.5 (17%) < 0.001
HDL-C [mg/dL] 50.3 ± 13.7 58.34 ± 16.6 < 0.001
Triglyceride [mg/dL] 143.5 (94%) 106 (61%) < 0.001
SHBG levels [nmol/L] 30.5 (22.8%) 38.45 (29.4%) 0.036
HDL-C – high density lipoprotein cholestrol; SHBG — sex hormone binding globulin
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[rs 6257]). TT, CT and CC genotype distributions 
of rs6257 polymorphism were 65%, 30%, 5% 
(MetS group) and 68%, 29%, 3% (control group), 
respectively (p = 0.742). GG, GA and AA genotype 
distributions of rs1799941 polymorphism were 
66%, 32%, 2% (MetS group) and 72%, 25%, 3% 
(control group), respectively (p = 0.424).
SHBG gene polymorphisms  
and MetS risk criteria
The total number of high risk alleles (G allele 
of the rs1799941 and T allele of rs6257) correlated 
positively with waist circumference (r = 0.203, 
p = 0.006) and negatively with SHBG levels 
(r = –0.291, p = 0.024) (Fig. 1). Women with 4 high 
risk alleles (GG [rs1799941] and TT [rs6257] geno-
type) displayed the highest waist circumference (110 
[17] cm), while subjects carrying £ 1 high risk 
alleles had elevated SHBG levels 45 [33] nmol/L 
(Fig. 1).
GG genotype of the rs1799941 was associa-
ted with low SHBG levels (Table 2): polymorphic 
subjects (AA or GA) had significantly higher SHBG 
levels compared to the wild type (GG); 44 (36) vs. 
29 (17), p = 0.031 and 56 (45) vs. 34 (20), p = 0.005 
for the study and the control groups respectively 
(Table 2, Fig. 2). A allele of rs 1799941 (A/G) poly-
morphism appeared to have protective effects and 
was associated with lower blood pressure, BMI and 
waist circumference (Table 2, Fig. 3). 
Table 2. Anthropometric and laboratory characteristics for sex hormone binding globulin genotype 
groups (rs 6257 and rs 1799941).
rs6257 (T/C) rs1799941 (A/G)
Metabolic syndrome subjects TT  
(n = 118)
TC+CC 
(n = 64)
P GG  
(n =120)
GA+AA  
(n=62)
P
SHBG levels [nmol/L] 36 (25%) 28 (11%) 0.146 29 (17%) 44 (36%) 0.031
SBP [mm Hg] 145 (19%) 144 (15%) 0.364 145 (18%) 142 (15%) 0.012
DBP [mm Hg] 85 (8%) 83 (12%) 0.527 85 (11%) 80 (11%) 0.040
BMI [kg/m2] 32 (7%) 33 (8%) 0.329 33 (7%) 31 (8%) 0.029
Waist circumference [cm] 98 (14%) 102 (19%) 0.196 102 (17%) 96 (14%) 0.003
Glucose levels [mg/dL] 110 (36%) 111 (28%) 0.657 108 (38%) 113 (31%) 0.669
HDL-C levels [mg/dL] 51 ± 14 49 ± 14 0.260 49 ± 13 52 ± 16 0.230
Triglyceride levels [mg/dL] 152 (89%) 140 (84%) 0.399 151 (87%) 132 (94%) 0.267
Control subjects TT  
(n = 81)
TC+CC 
(n = 38) 
P GG  
(n = 86)
GA+AA 
(n = 33)
P 
SHBG levels [nmol/L] 37 (29%) 38 (29%) 0.819 34 (20%) 56 (45%) 0.005
SBP [mm Hg] 125 (20%) 125 (26%) 0.544 125 (20%) 125 (17%) 0.592
DBP [mm Hg] 70 (15%) 70 (13%) 0.982 70 (15%) 70 (13%) 0.883
BMI [kg/m2] 25 (2%) 24 (3%) 0.196 25 (2%) 24 (3%) 0.656
Waist circumference [cm] 85 (4%) 85 (3%) 0.441 85 (4%) 84 (4%) 0.348
Glucose levels [mg/dL] 98 (16%) 101 (16%) 0.356 98 (15%) 102 (17%) 0.682
HDL-C levels [mg/dL] 58 ± 15 58 ± 20 0.992 58 ± 16 58 ± 18 0.938
Triglyceride levels [mg/dL] 106 (58%) 105 (62%) 0.758 104 (54%) 112 (74%) 0.531
SHBG — sex hormone binding globulin; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure;  
HDL-C — high density lipoprotein cholestrol
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Figure 1. The total number of high risk alleles (G allele of 
the rs1799941 and T allele of rs6257) and waist circum-
ference in subjects with metabolic syndrome. Median 
waist circumference is displayed for subjects with 4, 3, 
2 and £ 1 high risk alleles.
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Discussion
Most common complex traits (such as MetS) 
are caused by the non-linear interactions of nu-
merous genetic and environmental risk factors. 
The Turkish Adult Risk Factor Study reports that 
cardiovascular risk factors are highly prevalent in 
Turkish adults [14]. Epidemological studies display 
that MetS is extremely common (40%) among 
Turkish postmenopausal women [12]. Low SHBG 
level is an established biomarker of insulin resi-
stance and hyperinsulinemia [15]. Postmenopausal 
women with high SHBG levels have reduced risk 
of atherosclerosis and insulin resistance [16–18]. 
Genetic factors that can contribute to the dimi-
nished circulating SHBG levels are important in the 
onset of insulin resistance and MetS. San Antonio 
Family Heart Study displayed siginificant heritabi-
lity for serum SHBG levels [19]. The rs6257 and 
rs6259 SHBG polymorphisms were consistently 
associated with the circulating plasma levels of 
SHBG [19–22].
We studied SHBG gene polymorphisms in 
relation to MetS risk criteria in Turkish post-
menopausal women. We observed that A allele 
of rs1799941 polymorphism was associated with 
elevated SHBG levels and reduced blood pressure, 
and waist circumference. On the other hand, post-
menopausal women carrying more than 2 high risk 
alleles at the 2 loci (G allele of the rs1799941 and 
T allele of rs6257) displayed lower SHBG levels 
and an increased waist circumference. Therefore, 
polymorphic subjects (AG or AA) may be protected 
from MetS compared to the wild GG genotype. 
The study was cross sectional and comes with 
several limitations. Ethnic differences exist in 
the criteria and prevalence of MetS. Obviously, 
larger prospective studies are needed to confirm 
our observations. 
Genetic and environmental risk factors are 
important in the onset of MetS. We studied single 
locus and combined effects of the 2 loci on MetS 
risk criteria. Unlike Mendelian diseases that are 
associated with a single gene, MetS is likely to be 
caused by the non-linear interaction of numerous 
genetic and environmental risk factors. Therefore, 
a multilocus approach is neccessary to study gene-
-gene and gene-environmental risk interractions. 
Although rs1799941 is a synonymous polymor-
phism in intron 1, it is likely to be inherited with 
other loci that can alter SHBG levels. Similar-
ly, rs1799941 and rs6257 polymorphisms may 
have synergistic effects in determining MetS risk 
among postmenopausal women. 
The association between rs1799941 genotype 
and blood pressure or waist circumference was not 
observed in the control group. Our findings support 
the hypothesis that variations in the SHBG gene 
can cause genetic susceptibility to MetS which can 
be epigenetically modified by environmental risk 
factors (i.e. high calorie intake or lack of physical 
activity). 
Figure 2. Sex hormone binding globulin (SHBG) and 
body mass index levels for rs1799941 (A/G) genotype 
groups; MetS — metabolic syndrome group; BMI — body 
mass index; *p < 0.05. 
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Figure 3. Blood pressure (BP) and waist circumference 
for rs1799941 (A/G) genotype groups; *p < 0.05.
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The minor allele frequency of rs1799941 was 
lower among Turkish postmenopausal women 
compared to Spanish postmenopausal women 
(0.16 vs. 0.27) [23]. Minor allele frequencies in 
European and Sub-Saharan African population were 
reported as 0.22 and 0.031, respectively. In Asian 
population, minor allel frequency was lower than 
0.01 (http://www.ncbi.nlm.nih.gov/projects/SNP/ 
/snp_ref.cgi?rs=1799941). The lower frequency of 
A allele (rs1799941) can potentially contribute to 
the MetS endemic among Turkish postmenopausal 
women. 
Prior observations from different populations 
support the same hypothesis. SHBG gene poly-
morphisms were predictive of type 2 diabetes 
mellitus risk in the Physicians Health Study [6]. In 
a different study from Northern Spain, rs1799941 
(A/G) and rs6257 (T/C) polymorphisms displayed 
stronger associations with serum SHBG levels 
than the rs6259 (A/G) polymorphism [23]. Post me-
nopausal women with the AA genotype (rs1799941) 
showed 39% higher SHBG levels than GG genoty-
pe [23]. In the EPIC-Norfolk study, SHBG serum 
levels were 28% higher with the AA vs. the GG 
genotype (rs1799941) [10]. In a different study 
among Swedish men, AA genotype was again as-
sociated with higher SHBG levels [11].
Conclusions
In conclusion, A allele of SHBG gene rs1799941 
(A/G) polymorphism associates with higher serum 
SHBG levels and lower BMI, waist circumference 
and blood pressure in Turkish postnenopausal 
women. Prospective studies are needed to assess 
the cardiometabolic risk among SHBG genotype 
groups. Future studies should focus on the iden-
tification of genetic variants that can predispose 
postmenopausal women to MetS. Larger studies 
and novel bioinformatic methods (i.e. multifactor 
dimensionality reduction analysis) are needed to 
assess the role of SHBG genotype in concert with 
other genetic and environmental risk factors [24]. 
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